Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018017571) USES OF IL-12 AS A REPLACEMENT IMMUNOTHERAPEUTIC
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/017571 International Application No.: PCT/US2017/042600
Publication Date: 25.01.2018 International Filing Date: 18.07.2017
IPC:
A61K 38/20 (2006.01) ,C07K 14/54 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
20
Interleukins
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
54
Interleukins (IL)
Applicants:
NEUMEDICINES, INC. [US/US]; 133 N. Altadena Dr., #307 Pasadena, California 91107, US
Inventors:
BASILE, Lena A.; US
Agent:
SIMKIN, Michele; US
AGARWAL, Pavan K.; US
BECK, George; US
BERKOWITZ, Benjamin; US
BRINCKERHOFF, Courtenay; US
FELDHAUS, John J.; US
KAMINSKI, Michael D.; US
LAW, Glenn; US
QUILLIN, George E.; US
MAEBIUS, Stephen; US
RAWLINS, Andrew E.; US
SCHORR, Kristel; US
Priority Data:
62/363,64818.07.2016US
Title (EN) USES OF IL-12 AS A REPLACEMENT IMMUNOTHERAPEUTIC
(FR) UTILISATIONS DE IL-12 COMME AGENT IMMUNOTHÉRAPEUTIQUE DE REMPLACEMENT
Abstract:
(EN) Aspects and embodiments of the present disclosure provide therapeutic methods comprising interleukin 12 (IL-12) as a replacement immunotherapeutic. The method comprises administering a physiological dose of exogenous IL-12 to a subject.
(FR) Des aspects et des modes de réalisation de la présente invention concernent des méthodes thérapeutiques dans lesquelles on utilise l'interleukine 12 (IL -12) en tant qu'agent immunothérapeutique de remplacement. La méthode comprend l'administration d'une dose physiologique d'IL-12 exogène à un sujet.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)